Taweerutchana Rutchaporn, Lumlerdkij Natchagorn, Vannasaeng Sathit, Akarasereenont Pravit, Sriwijitkamol Apiradee
Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Salaya, Thailand.
Center of Applied Thai Traditional Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Salaya, Thailand.
Evid Based Complement Alternat Med. 2017;2017:6581390. doi: 10.1155/2017/6581390. Epub 2017 Nov 28.
Studies showed effects of (MO) on lowering blood sugar levels in animal and diabetes patients. The aims of this study were to determine the effect of MO leaf capsules on glucose control in therapy-naïve type 2 diabetes mellitus (T2DM) and to evaluate its safety.
This was a prospective randomized placebo controlled study. Therapy-naïve T2DM was randomly assigned to receive either 8 grams per day of MO leaf capsules (MO leaf group) or placebo for 4 weeks. Clinical and laboratory characteristics were recorded at screening and at the end of 4-week study. 9-point plasma glucose was obtained before and every week during the study.
Thirty-two T2DM patients were enrolled. The mean age was 55 years and the mean HbA1C was 7.0%. There was no significant difference in FPG and HbA1C between groups. MO leaf group had SBP reduction by 5 mmHg as compared to baseline but this difference had no statistical significance. There were no adverse effects of MO leaf.
leaf had no effect on glycemic control and no adverse effects in T2DM. Interestingly, this study demonstrated that MO leaf had a tendency on blood pressure reduction in T2DM, and this result needs further investigation.
研究表明（MO）对动物和糖尿病患者有降低血糖水平的作用。本研究的目的是确定MO叶胶囊对初治2型糖尿病（T2DM）患者血糖控制的影响，并评估其安全性。
这是一项前瞻性随机安慰剂对照研究。将初治T2DM患者随机分为两组，一组每天服用8克MO叶胶囊（MO叶组），另一组服用安慰剂，为期4周。在筛查时和4周研究结束时记录临床和实验室特征。在研究前及研究期间每周采集9点血糖值。
共纳入32例T2DM患者。平均年龄为55岁，平均糖化血红蛋白（HbA1C）为7.0%。两组间空腹血糖（FPG）和HbA1C无显著差异。与基线相比，MO叶组收缩压（SBP）降低了5 mmHg，但差异无统计学意义。MO叶无不良反应。
MO叶对T2DM患者的血糖控制无影响，也无不良反应。有趣的是，本研究表明MO叶有降低T2DM患者血压的趋势，这一结果需要进一步研究。
